RT Journal Article
SR Electronic
A1 Freeman, Sara
T1 Romosozumab Bone Benefits at 1 Year versus Teriparatide in Postmenopausal Women
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 17
SP 17
OP 17
DO 10.1177/155989771417008
UL http://mdc.sagepub.com/content/14/17/17.1.abstract
AB The investigational drug romosozumab produced significantly greater improvements in volumetric bone mineral density (vBMD) and volumetric bone mineral content (vBMC) compared with both placebo and teriparatide in postmenopausal women with low bone mass in a substudy of an international multicenter randomized Phase 2 trial.